In 2006 Dr. Ellies founded OsteoGeneX Inc (OGX), and has worked to develop the unique business strategy for a strategic partner to get market revenue quickly, with a de-risked efficacious orally available drug that will increase bone density. Prior to launching OGX, Dr. Ellies was at the Stowers Medical Research Institute in Kansas City, MO. While at the Stowers Institute under the direction of Dr Krumlauf, Debra was the key scientist in the epochal discovery of Sclerostin as a modulator of the WNT pathway. Dr. Ellies was also part of the scientific team which discovered that the CCN family also functioned via WNT signaling. Furthermore, Ellies & Krumlauf were the first to report that Sclerostin blocking antibodies function by blocking the WNT pathway. Prior to her work at Stowers, Dr. Ellies conducted basic research on the developmental significance of programmed cell death, the role in Wnt signaling and managed a laboratory at Ottawa Civic Hospital in Ottawa, Canada. In addition to her remarkable successes in the laboratory, Dr. Ellies co-founded the Brian Ellies Esophageal Cancer Prevention Fund, which works to educate the public and promote awareness of esophageal cancer prevention. Dr. Ellies is the author of several international key scientific manuscripts in the area of signal transduction, and of a number of patents, and a reviewer for Center for Scientific Reviewer at NIH, and a Trustee for MRIGlobal. She received her Ph.D. from Guy’s Hospital London, UK, under the supervision of Prof. Andrew Lumsden, FRS; M.Sc. from University Ottawa, LOEB Research Institute, Canada.
Bruce W. Jenett is Partner and past Co-Chair of the Global Life Sciences Sector at DLA Piper in East Palo Alto, California. Mr. Jenett is a renowned life science lawyer who brings over 25 years of industry experience focused on the representation of domestic and international business and finance clients in the life sciences industry. He received his J.D. from Georgetown University Law Center and a B.A. from Princeton. Mr Jenett is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Among his many accomplishments, Mr. Jenett handled one of the largest ag-bio partnering deals in history, as well as one of the largest partnering deals ever done by an Irish venture capital-backed biotechnology company with a major pharmaceutical company. A frequent speaker on corporate and finance issues to both business and attorney audiences, Mr. Jenett is also a member of the Bioethics Committee of BIO, and of the BayBio Board of Directors, and he is a member of, and Co-Chair of the Strategic Planning Committee of, San Francisco Mayor Gavin Newsom’s Biotech Advisory Council. Chambers & Partners: America’s Leading Lawyers for Business consistently names him one of the leading business lawyers in the United States.
F. Scott Kimball, Ph.D., joined OGX in 2010 as director of chemistry. Dr. Kimball’s training as a medicinal/synthetic organic chemist is exemplified by proven innovation applied to conceptualization and execution of novel synthetic transformations used to overcome published limitations directed against structurally complex natural products. His expertise includes the first multistep total synthesis of structurally complex chiral natural products and enantio-specific synthesis and characterization of related small molecule analogs. During his work, he designed and undertook the synthesis of analog libraries to probe the structure-activity requirements of several lead compounds. Dr. Kimball obtained his Ph.D. at the University of Kansas under the direction of Prof. Gunda Georg and then trained at The Scripps Research Institute under the direction of Prof. Dale Boger. He had the privilege to be taught medicinal chemistry under two mentors internationally recognized for their talent in drug development.
Mike joined OsteoGeneX in January 2013, serving as a consultant, brings extensive experience in all aspects of corporate development and operations, including finance. Mr. Riley was most recently Vice President Intellectual Property (IP) for Demira, Inc. From 2006 to 2011 Mr. Riley was Vice President Corporate Development and IP for Intradigm Corporation prior to its acquisition by Silence Therapeutics plc (AIM:SLN) where he served as Sr. Vice President Corporate Development and IP. Prior to that, Mr. Riley was Sr. Corporate Counsel for Abgenix, Inc. (2004-2006) and Corporate Counsel for Celltech Group plc (2000-2004). From 1996 Mr. Riley worked at two nationally recognized law firms including Kansas City based Shook, Hardy and Bacon as an associate in the Intellectual Property group. Mr. Riley has a J.D. from the University of North Dakota School of Law, a M.Sc. in biochemistry from the University of North Dakota School of Medicine and a B.A. from St. Mary’s University in Minnesota.
Dr. Rosenberg joined OsteoGeneX in March 2007 as Chief Medical Officer. Dr. William S. Rosenberg, M.D., is an innovator in both his practice of medicine and in the development of new technologies and devices in life sciences. Dr. Rosenberg specializes in complex spinal surgery as a neurosurgeon with Midwest Neurosurgery Associates in Kansas City. Prior to joining his current group, he was Director of the Neurospinal Disorders Program at University of California, San Francisco and Co-Founder of the Spine Biomechanics Laboratory at University of California, Berkeley. Dr. Rosenberg received his medical degree from Harvard Medical School and trained in neurosurgery at Massachusetts General Hospital in Boston. In addition to his medical practice, Dr. Rosenberg has served as a consultant for a number of medical device companies in various stages of development and holds several patents for surgical devices and techniques.